Pharmacokinetics of a sustained release formulation of PDGFβ-receptor directed carrier proteins to target the fibrotic liver

被引:23
|
作者
van Dijk, F. [1 ,2 ]
Teekamp, N. [1 ]
Beljaars, L. [2 ]
Post, E. [2 ]
Zuidema, J. [3 ]
Steendam, R. [3 ]
Kim, Y. O. [4 ]
Frijlink, H. W. [1 ]
Schuppand, D. [4 ,5 ]
Poelstra, K. [2 ]
Hinrichs, W. L. J. [1 ]
Olinga, P. [1 ]
机构
[1] Univ Groningen, Groningen Res Inst Pharm, Dept Pharmaceut Technol & Biopharm, Groningen, Netherlands
[2] Univ Groningen, Groningen Res Inst Pharm, Dept Pharmacokinet Toxicol & Targeting, Groningen, Netherlands
[3] InnoCore Pharmaceut, Groningen, Netherlands
[4] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Res Ctr Immune Therapy, Inst Translat Immunol, Mainz, Germany
[5] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA
关键词
Controlled release; Biodegradable polymeric microspheres; PDGF beta-receptor targeted drug carrier; Protein delivery; in vitro in vivo correlation; Liver fibrosis; GROWTH-FACTOR RECEPTOR; DRUG-DELIVERY; ANTIFIBROTIC THERAPIES; POLYMERIC MICROSPHERES; MULTIBLOCK-COPOLYMER; INTERFERON-GAMMA; IN-VIVO; FIBROSIS; IMPLANTS; MICE;
D O I
10.1016/j.jconrel.2017.11.029
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Liver fibrogenesis is associated with excessive production of extracellular matrix by myofibroblasts that often leads to cirrhosis and consequently liver dysfunction and death. Novel protein-based antifibrotic drugs show high specificity and efficacy, but their use in the treatment of fibrosis causes a high burden for patients, since repetitive and long-term parenteral administration is required as most proteins and peptides are rapidly cleared from the circulation. Therefore, we developed biodegradable polymeric microspheres for the sustained release of proteinaceous drugs. We encapsulated the drug carrier pPB-HSA, which specifically binds to the PDGF beta R that is highly upregulated on activated myofibroblasts, into microspheres composed of hydrophilic multi-block copolymers composed of poly(L-lactide) and poly ethylene glycol/poly(is an element of-caprolactone), allowing diffusion-controlled release. Firstly, we estimated in mice with acute fibrogenesis induced by a single CCl4 injection the half-life of I-125-labeled pPB-HSA at 40 min and confirmed the preferential accumulation in fibrotic tissue. Subsequently, we determined in the Mdr2-/- mouse model of advanced biliary liver fibrosis how the subcutaneously injected microspheres released pPB-HSA into both plasma and fibrotic liver at 24 h after injection, which was maintained for six days. Although the microspheres still contained protein at day seven, pPB-HSA plasma and liver concentrations were decreased. This reduction was associated with an antibody response against the human albumin-based carrier protein, which was prevented by using a mouse albumin-based equivalent (pPB-MSA). In conclusion, this study shows that our polymeric microspheres are suitable as sustained release formulation for targeted protein constructs such as pPB-HSA. These formulations could be applied for the long-term treatment of chronic diseases such as liver fibrosis.
引用
收藏
页码:258 / 265
页数:8
相关论文
共 50 条
  • [31] SINGLE-DOSE PHARMACOKINETICS OF KAPANOL(TM), A NEW ORAL SUSTAINED-RELEASE MORPHINE FORMULATION
    MACCARRONE, C
    WEST, RJ
    BROOMHEAD, AF
    HODSMAN, GP
    DRUG INVESTIGATION, 1994, 7 (05): : 262 - 274
  • [32] Local injection of a sustained-release antiandrogen formulation into a target prostatic site: an experimental study
    Goya, Nobuyuki
    Gotanda, Kotaro
    Sasaki, Takako
    Okada, Mami
    Tomizawa, Yasuko
    Toma, Hiroshi
    BJU INTERNATIONAL, 2007, 99 (01) : 202 - 206
  • [33] Local injection of sustained-release antiandrogen formulation into a target prostatic site: An experimental study
    Goya, Nobuyuki
    Gotanda, Kotaro
    Tomizawa, Yasuko
    Toma, Hiroshi
    JOURNAL OF UROLOGY, 2007, 177 (04): : 515 - 515
  • [34] A novel sustained-release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers
    Berends, Cecile L.
    Pagan, Lisa
    van Esdonk, Michiel J.
    Klarenbeek, Naomi B.
    Bergmann, Kirsten R.
    Moerland, Matthijs
    van der We, Vincent
    de Visser, Saco J.
    Buller, Hans
    de Loos, Frans
    de Vries, Wouter S.
    Waals, Hans
    de Leede, Leo G. J.
    Burggraaf, Jacobus
    Kamerling, Ingrid M. C.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (02):
  • [35] An injectable microparticle formulation for the sustained release of the specific MEK inhibitor PD98059: in vitro evaluation and pharmacokinetics
    Naguib, Youssef W.
    Givens, Brittany E.
    Ho, Giang
    Yu, Yang
    Wei, Shun-Guang
    Weiss, Robert M.
    Felder, Robert B.
    Salem, Aliasger K.
    DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2021, 11 (01) : 182 - 191
  • [36] Pharmacokinetics of a Sustained-release Formulation of Meloxicam After Subcutaneous Administration to Hispaniolan Amazon Parrots (Amazona ventralis)
    Guzman, David Sanchez-Migallon
    Court, Michael H.
    Zhu, Zhaohui
    Summa, Noemie
    Paul-Murphy, Joanne R.
    JOURNAL OF AVIAN MEDICINE AND SURGERY, 2017, 31 (03) : 219 - 224
  • [37] Sustained release dosage form of noscapine HCl using hot melt extrusion (HME) technique: formulation and pharmacokinetics
    Arvind Bagde
    Nilkumar Patel
    Ketan Patel
    Ebony Nottingham
    Mandip Singh
    Drug Delivery and Translational Research, 2021, 11 : 1156 - 1165
  • [38] Sustained release dosage form of noscapine HCl using hot melt extrusion (HME) technique: formulation and pharmacokinetics
    Bagde, Arvind
    Patel, Nilkumar
    Patel, Ketan
    Nottingham, Ebony
    Singh, Mandip
    DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2021, 11 (03) : 1156 - 1165
  • [39] An injectable microparticle formulation for the sustained release of the specific MEK inhibitor PD98059: in vitro evaluation and pharmacokinetics
    Youssef W. Naguib
    Brittany E. Givens
    Giang Ho
    Yang Yu
    Shun-Guang Wei
    Robert M. Weiss
    Robert B. Felder
    Aliasger K. Salem
    Drug Delivery and Translational Research, 2021, 11 : 182 - 191
  • [40] Rat pharmacokinetics and pharmacodynamics of a sustained release formulation of the GABAA α5-selective compound L-655,708
    Atack, JR
    Pike, A
    Clarke, A
    Cook, SM
    Sohal, B
    McKernan, RM
    Dawson, GR
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (05) : 887 - 893